@article {Hemady2021.07.23.21261027, author = {Chad Lance Hemady and Lydia Gabriela Speyer and Aja Louise Murray and Ruth Harriet Brown and Franziska Meinck and Deborah Fry and Huyen Do and Siham Sikander and Bernadette Madrid and Asvini Fernando and Susan Walker and Michael Dunne and Sarah Foley and Claire Hughes and Joseph Osafo and Adriana Baban and Diana Taut and Catherine L. Ward and Vo Van Thang and Pasco Fearon and Mark Tomlinson and Sara Valdebenito and Manuel Eisner}, title = {Patterns of adverse childhood experiences and associations with prenatal substance use and poor infant outcomes in a multi-country cohort of mothers: A Latent Class Analysis}, elocation-id = {2021.07.23.21261027}, year = {2021}, doi = {10.1101/2021.07.23.21261027}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Aims This paper explores the number and characterization of latent classes of adverse childhood experiences across the Evidence for Better Lives Study cohort and investigates how the various typologies link to prenatal substance use (i.e., smoking, alcohol, and illicit drugs) and poor infant outcomes (i.e., infant prematurity and low birth weight). Participants and setting A total of 1,189 mother-infant dyads residing in eight diverse low- and middle-income countries (LMICs) were recruited. Methods Latent class analysis using the Bolck, Croon, and Hagenaars (BCH) 3-step method with auxiliary multilevel logistic regressions with distal outcomes were performed. Results The LCA identified three high-risk classes and one low-risk class, namely: (1) highly maltreated (7\%, n = 89), (2) emotionally and physically abused with intra-familial violence exposure (13\%, n = 152), (3), emotionally abused (40\%, n = 474), and (4) low household dysfunction and abuse (40\%, n = 474). Overall, across all latent classes, there were low probabilities of prenatal substance use and poor infant outcomes. However, pairwise comparisons between classes indicate that class 1 and 3 had higher probabilities of prenatal illicit drug use compared to class 4. Additionally, class 2 had higher probability of low birth weight compared to the three remaining classes. Conclusion The results further our understanding of the dynamic and multifaceted nature of ACEs. More research grounded on LMICs is warranted with more attention to various parameters of risk exposure (i.e., severity, duration, chronicity).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work of the Evidence for Better Lives Study was supported by the Jacobs Foundation, UBS Optimus Foundation, Fondation Botnar, the Consuelo Zobel Alger Foundation, the British Academy, the Cambridge Humanities Research Grants Scheme, the ESRC Impact Acceleration Account Programme, a Queensland University of Technology Postgraduate Research Award, Higher Degree Research Student Supplementary Research Funding from Queensland University of Technology, the University of Edinburgh College Office for the College of Arts, the Humanities and Social Sciences SFC ODA Global Challenges Internal Fund, the University of Cambridge GCRF Quality Research Fund and the Wolfson Professor of Criminology Discretionary Fund. The views expressed are those of the authors and not necessarily those of the funding bodies. CLH is supported by the Edinburgh Centre for Data, Culture and Society. FM was supported by the European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme [Grant Agreement Number 852787] and the UK Research and Innovation Global Challenges Research Fund [ES/S008101/1].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Evidence for Better Lives Study protocol for recruitment and collection of data has been approved by the following ethics boards: University of Cambridge, School of Social Sciences (18/180) and the Human Biology Research Ethics Committee, UK HBREC.2018.27; University of the Philippines Manila - Research Ethics Board, Philippines, UPMREB 2018-558-01; The Institutional Ethics Committee of Hue University of Medicine and Pharmacy, Vietnam, H2018/430; University of Kelaniya, Faculty of Medicine, Ethics Review Committee, Sri Lanka, P/208/11/2018; National Bioethics Committee (NBC), Pakistan, 4-87/ NBC-364/19/1487; Consiliul Stiintific - Universitatea Babes-Bolyai, Romania, 18.362/11.10.2018; University of Cape Town, Department of Health, Western Cape Government, South Africa, WC_201911_009; Health Impact Assessment - Western Cape Government; University of Cape Town, Faculty of Health Sciences, Human Research Ethics Committee, South Africa, 057/2019. Health Research Ethics Committee (HREC) at Stellenbosch University, South Africa, N18/09/099; Ghana Health Service Ethics Review Committee, GHS-ERC008/11/18; University of the West Indies Ethics Committee, Jamaica, ECP 212, 17/18.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, CLH, upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2021/07/29/2021.07.23.21261027}, eprint = {https://www.medrxiv.org/content/early/2021/07/29/2021.07.23.21261027.full.pdf}, journal = {medRxiv} }